RxDoctor Payments Data

Mahesh Mathews, MD

Family Medicine · Scottsdale, AZNPI 1356570568

Payments from drug & device makers

$576in general payments, 2019–2025

Across 10 payments — averaging $57.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$149
  • Novo Nordisk$142
  • Vifor Pharma, Inc.$125
  • AbbVie$124
  • Abbott$24
  • Amgen$13

What the payments were for

  • Food & beverage$576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca3$149
Novo Nordisk2$142
Vifor Pharma, Inc.1$125
AbbVie2$124
Abbott1$24
Amgen1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$576 in reported general payments places this provider in the 60th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$140,718
Medicare patients
369
Services billed
2,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$174,282
OzempicSemaglutide52$63,655
MyrbetriqMirabegron60$60,873
MounjaroTirzepatide52$55,486
CreonLipase/Protease/Amylase15$43,744
JanuviaSitagliptin Phosphate16$26,195
MultaqDronedarone Hcl15$25,331
Repatha SureclickEvolocumab25$24,801
FarxigaDapagliflozin Propanediol18$24,583
XareltoRivaroxaban14$18,799
EntrestoSacubitril/Valsartan11$17,726
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,714
TradjentaLinagliptin11$13,027
SynthroidLevothyroxine Sodium119$11,358
Rosuvastatin Calcium518$8,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$142$63,65552 claims
AbbVieCreon, Synthroid$124$55,102134 claims
AstraZenecaFarxiga$149$24,58318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →